All News
Aware of COPA syndrome?
➡️Rare cause of immune-mediated lung dz
➡️Mimics RA-ILD, SLE, & vasculitis
➡️Adult-onset cases reported
Abst#0529 determined that mutations in the COPA gene underlie some cases of severe pulmonary fibrosis.
#ACR21 @RheumNow https://t.co/mCx3eT7Pv8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
📢Do not miss the #Lupus Faculty panel discussion @RheumNow on a selection of interesting abstracts presented on Day 2 📝#ACR21 @KDAO2011 @Janetbirdope @bella_mehta @_Castillo_Pedro @RHEUMarampa https://t.co/e0v4qQIE4h
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What to do if pt on a TNFi develops cancer? Can you safely restart TNFi later? Depends on cancer, timing - how long ago was cancer, Rx and patient preference. Data diff from RABBIT registry vs British bio registry @RheumNow #ACR21 #ACRBest 7S413 Have a look https://t.co/q9SFKlFJzg
Janet Pope Janetbirdope ( View Tweet)
Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks
#ACR21 @RheumNow https://t.co/Dl5WPo7mmj
Akhil Sood MD AkhilSoodMD ( View Tweet)
This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion.
RWE Cohort: HR 1.01 (0.83-1.22)
RCT-dup Cohort: HR 1.19 (0.86-1.64)
ORAL Surveillance: HR 1.48 (1.04-2.09)
Interesting day 4 ahead!
great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr
David Liew drdavidliew ( View Tweet)
Does concomitant SJS affect tx effectiveness in RA?
Abst#0839 suggest yes!
➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS
BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores.
What's your clinical experience with this?
#ACR21 @Rheumnow https://t.co/TIc3raMOSJ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
A worthwhile point:
despite historic concerns, in the modern era TNFi can used safely & well in HIV pts
18y follow-up, all pts high CD4
(their starting criteria: CD4>200, VL <60,000)
no reported opportunistic infx
good arthritis response
#ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew drdavidliew ( View Tweet)
Abst#0572: In US veterans w/ RA followed for 17 yrs, several cytokines+chemokines
⭐️Associated w/ ↑ risk of incident MACE independent of typical CVD RF & RA activity
&
⭐️Predicted MACE even if in LDA/remission
WOW! We need to do better @ CVD risk strat!
#ACRBest @RheumNow https://t.co/J74rRa9EQE
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
#ACR21 #Abstr0865 It’s time for T2T to achieve LLDAS in #lupus. In a study of N=2040 pts, mortality was 2.3% mainly due to infection. Remission off steroid was the best but only met in 14%. LLDAS-50 achieved in 48% pts and ⬇️mortality by 56% @RheumNow https://t.co/CddqMuFIOM https://t.co/g346Cbybep
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Join the @RheumNow faculty tonight for a recap of Day 2 at #ACR21
⏰19:00 ET
⏰Midnight GMT- I promise to be well-caffeinated to present my many highlights from today! 😄
📺Register via the Zoom link below or watch on Youtube https://t.co/6HIQGR5T8z
Mrinalini Dey DrMiniDey ( View Tweet)
beautifully chaired by @cappelliMD
also elegant talk on 'M-triad' by the always articulate @lovetolearn27, made me think about my pt on the ward right now!
#ACR21 @RheumNow @CCalabreseDO @LCalabreseDO @got_rheum @MarieKostine @lexmeara @ReidMDMPH @NilashaGhosh @RheumDr_Nina https://t.co/2iu6zWp8Ge
David Liew drdavidliew ( View Tweet)
*️⃣CT-P13=1st monoclonal biosimilar to infliximab (IFX)
⭐️ReFLECT: 1370 French pts (142 RA, 411 axSpA, 96 PsA)
→2 groups: IFX-naïve starting CT-P vs switching from IFX to CT-P
*️⃣CT-P13 induced improvement in IFX-naïve & maintained dz in pts switched
Abst#0817 #ACR21 @RheumNow https://t.co/bASmGvhuIS
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Great talk by @saadhealth #ACR21 & interesting to compare myocarditis irAEs to inflamm arthritis irAEs:
similar:
- importance of confirming dx well
- cautious adoption steroid-sparing Rx
different:
- clear benefit hard/early Rx
- dx metrics aided by tech
#ACR21 7S404 @RheumNow https://t.co/mFjM3ZlZaP
David Liew drdavidliew ( View Tweet)
Catching up with #ACR21 content?🧐 Please read my article on updates of safety and effectiveness of #COVID19 vaccines in people with #lupus @RheumNow https://t.co/pru9dTH4z7
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
⭐️2 polyunsaturated fatty acid lipid mediator profiles are significantly associated w/ incident inflammatory arthritis in ACPA+ pts
➡️If validated, this would be of great utility in determining which pts w/ pre-clinical sero+ should be treated!
Abst#0590 at #ACR21 @RheumNow https://t.co/KGEwiY6G2Q
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Abstr 0983 mRNA SARS-CoV-2 Vaccine in RA Patients
Rubbert-Roth and colleagues found:
- RA patients developed anti-S1 antibodies slower and lower compared to controls
- Reduced titers among Abatacept & JAKi users
#ACR21 @RheumNow https://t.co/sXW8d53O8m
Akhil Sood MD AkhilSoodMD ( View Tweet)
Rheumatologists and Health Professionals: Join us tonight for RheumNow's #ACR21 Daily Recap at 7pm Eastern time . Register via the Zoom link below.
https://t.co/sxQuP28APX
Or visit our YouTube channel-RheumNow.
https://t.co/sohrPTB16S https://t.co/LXWaBFOdHO
Dr. John Cush RheumNow ( View Tweet)
Post-Hoc of ASCORE trial:
➡️RA w/ mod-high dz on SQ ABAtacept as 1st line tx w/ better retention vs receiving it as 2nd line tx independent of b/l duration of dz
➤Do you use ABA as 1st line treatment for RA, when/if insurance allows? Comment below!
Abst#0816 #ACR21 @RheumNow https://t.co/TRJga4OfiW
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)